Chlamydia Infection Diagnostics Market Clinical Research and Analysis Report 2020-2026

(MENAFN- Ameliorate Solutions)

Chlamydia is a curable and common, sexually transmitted infection that may not cause symptoms. It spreads through vaginal, anal, and oral sex. The infection is carried in semen (cum), pre-cum, and vaginal fluids. Chlamydia can infect the penis, vagina, cervix, anus, urethra, eyes, and throat.

The report presents an in-depth assessment of the Global Chlamydia Infection Diagnostics including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Global Chlamydia Infection Diagnostics investments from 2020 till 2025.

Owing to the rising prevalence of chlamydia and major shift from conventional technologies to molecular diagnostics the market studied is growing rapidly. In 2016, WHO estimated 376 million new infections with 1 of 4 being STIs, out of which, the incidence of chlamydia was 127 million, gonorrhea was 87 million, and syphilis was 6.3 million. Furthermore, there is a growing focus on rapid testing since it delivers a quick results. In 2018, the NIBIB-funded researchers authorized a rapid STD test that delivered accurate results in about 30 minutes for chlamydia, allowing patients to receive treatment immediately, thereby curtailing further spread of disease. There is a negative social perception of STDs, as they are caused due to sexual interactions. Hence, people are more conscious about their privacy and social status, when it comes to STD testing, which is limiting the growth of the market studied.

Click the link to get a free Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/01091744697/chlamydia-infection-diagnostics-market-growth-trends-and-forecast-2020-2025/inquiry?source=MW & Mode=21

Top Leading Manufactures-

Abbott Laboratories, Becton, Dickinson and Company, BIO-RAD LABORATORIES, Danaher Corporation (Cepheid), DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic, Inc., QUIDEL CORPORATION, SAVYON DIAGNOSTICS, TRINITY BIOTECH

Key Market Trends

Laboratory-Based Tests dominates the Global Chlamydia Infection Diagnostics Market

- The Nucleic Acid Amplification Test (NAAT) is the recommended method. It is a molecular test that detects DNA, the genetic material of Chlamydia trachomatis.
- The method is usually more sensitive and specific than the other chlamydia tests and it can be performed on a vaginal swab taken from women, as well as on urine from both men and women, and thus it eliminates the requirement for a pelvic exam in women.
- Most of the time, NAATs can be used with both urine and vaginal samples for women. However, only some are approved for use with samples taken from men as well.
- Furthermore, new diagnostic tools can be developed for a fraction of the cost and in much less time than either a drug or a vaccine which suggests that focused funding and effort should be able to produce viable tools in a relatively short period of time.

Inquire for Discount:

https://www.marketinsightsreports.com/reports/01091744697/chlamydia-infection-diagnostics-market-growth-trends-and-forecast-2020-2025/discount?source=MW & Mode=21

North America Dominates the Global Chlamydia Infection Diagnostics Market

North America holds a leading position in the Chlamydia Infection Diagnostics market during the forecast period. In 2017, a total of 1,708,569 chlamydial infections were reported to the Centre for Disease Prevention and Control (CDC) in 50 states of the United States. During 2016-2017, the rate of reported cases increased by 6.9%, from 494.7 to 528.8 cases per 100,000 population. The National Health and Nutrition Examination Survey (NHANES) is a nationally representative survey of the US civilian, a non-institutionalized population that provides an important measure of chlamydia disease burden in respondents aged 14-39 years. In March 2019, USFDA granted clearance to diagnostic tests for extragenital testing for chlamydia and gonorrhea, Aptima Combo 2 Assay, to Hologic Inc. and Xpert CT/NG to Cepheid. Hence, the high rate of diagnosis, high adoption and awareness among the people and the introduction of new and technologically advanced tests are also contributing to the growth of the market in North America.

– Key Strategic Developments : The study also includes the key strategic developments of the market, comprising R & D, new product launch, M & A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a Global and regional scale.

– Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

– Analytical Tools: Global Chlamydia Infection Diagnostics Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter's five forces analysis, feasibility study, and investment return analysis have been used to analyzed the growth of the key players operating in the market.

The research includes historic data from 2014 to 2020 and forecasts until 2025 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Media Contact Us:

Irfan Tamboli (Head of Sales) – Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

 | 

MENAFN17012020007010643ID1099568055